In a report released today, Shirley Chen from Barclays maintained a Sell rating on Novartis AG, with a price target of CHF90.00. The company’s shares closed yesterday at CHF105.80.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Chen is a 2-star analyst with an average return of 3.8% and a 55.00% success rate. Chen covers the Healthcare sector, focusing on stocks such as AstraZeneca, Novartis AG, and GlaxoSmithKline.
The word on The Street in general, suggests a Hold analyst consensus rating for Novartis AG with a CHF101.18 average price target.
NOVN market cap is currently CHF200.3B and has a P/E ratio of 17.60.
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Trump Trade: White House announces drug pricing deal with Pfizer
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says
- Immatics appoints Venkat Ramanan as Chief Financial Officer
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/AI%20software%20engineering%20by%20Tapati%20Rinchumrus%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Apple%20Inc%20phone%20and%20data-by%20Anderson%20Reis%20via%20Shutterstock.jpg)